DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation

Information source: Adapt Produtos Oftalmológicos Ltda.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Eye Infection/Inflammation Other

Intervention: moxifloxacin 0,5% + prednisolone 1% (Drug); moxifloxacin/prednisolone combination (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Adapt Produtos Oftalmológicos Ltda.

Official(s) and/or principal investigator(s):
Cristina Mucioli, Dra., Study Chair, Affiliation: Universidade Federal de São Paulo - Hospital São Paulo - UNIFESP

Overall contact:
Rubens Belfort, investigator, Phone: 5511 5572-6443, Email: prof.belfort@clinicabelfort.com.br


This is a Unicentric, double-blind, randomized, two-arm, parallel-group study to demonstrate the efficacy of moxifloxacin/prednisolone acetate fixed combination compared with individual administration of moxifloxacin + acetate Prednisolone Eye drops in Prevention of Post Operative Inflammation and Infection in LASIK surgery.

Clinical Details

Official title: Efficacy of Moxifloxacin 0.5%/Prednisolone 1% Fixed Combination Compared With Individual Administration of Moxifloxacin 0.5% and Prednisolone 1% in the Prevention of Post Operative Inflammation in Patients Having Lasik Surgery

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Day 15 Evaluation of Anterior Chamber

Secondary outcome: day 15 physician´s follow-up impression of inflammatory reaction score

Detailed description: antibiotic/steroid combination compared to individuals components 15 days of treatment


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Men or women of any race, between 18 and 50 years of age up to 8 degrees of myopia or

hyperopia of up to 04 degrees or up to 3 degrees without astigmatism and other eye problems associated.

- Able to understand and provide informed consent,

- Willingness to complete all required study visits,

- Willingness to undergo surgery to correct grade (myopia, astigmatism, hyperopia) by

LASIK in both eyes (at the same surgical or surgical procedures separated) or in only one eye.

- Examination of normal fundus by direct ophthalmoscopy or indirect;

- Measurements of intraocular pressure (IOP), treated or untreated, less than or equal

to 20 mmHg. Individuals with glaucoma / ocular hypertension are eligible if their blood pressure is controlled by a single ocular hypotensive agent with the exception noted in criterion of exclusion. 16.

- Women who may become pregnant (those that are not surgically sterile or

postmenopausal) may participate in the study if they meet all the following conditions: a)not breastfeeding; b)have a negative pregnancy test at screening prior to recruitment; c)agree to submit to a urine test for pregnancy at the time of its withdrawal from the study; d)not to conceive during the study period; e)are using birth control methods appropriate and agrees to continue to use birth control methods appropriate for the duration of the study (the methods of birth control are adequate:

hormonal contraceptives - oral, implantable or injectable; mechanics - spermicide

associated with a barrier method like a condom or diaphragm, IUD, or sterilization of the partner). Exclusion Criteria:

- Glaucoma or intraocular hypertension not controlled;

- Use of nonsteroidal antiinflammatory drugs (NSAIDs) ocular topical or systemic drugs

(NSAIDs) during the study and the 14 days prior to study entry, except for an allowed daily dose of aspirin low-dose (100 mg);

- Ocular anti-infective drug use during the study and within 30 days prior to study

entry or any other eye medicines with the exception noted in criterion Insertion 6.

- Topical steroids, inhaled or systemic ocular during the study and the 14 days prior

to study entry;

- Ocular trauma in the eye prior to operate (including intraocular surgery in the

previous twelve months due to trauma or cataract in the past);

- History of chronic ocular inflammatory disease or recurrent (ie, iritis, scleritis,

uveitis, iridocyclitis, rubeosis iridis) in the eye to be operated;

- Any intraocular inflammation (score of cells than Grade 0) to be present during the

examination of slit lamp or ocular pain increased in the Grade 1 - 2 Day in the study

eye (eye operation);

- Proliferative diabetic retinopathy (eye operation) non-proliferative diabetic

retinopathy, moderate to severe (eye operation);

- Uncontrolled diabetes mellitus;

- Patients with vision in one eye or vision not correctable to LogMAR 1. 0 or better in

each eye using the ETDRS framework;

- Participation in any other clinical study within 12 months prior to surgery, pregnant

women, lactating or under conditions of breeding methods that are not using adequate birth control (as defined in the criteria for inclusion, above);

- Known or suspected allergy or hypersensitivity to moxifloxacin, steroids, topical

anesthetics or any other component of the study medication;

- History or other evidence of severe illness, or other systemic conditions that may

cause the patient, in the opinion of the Investigator, the study is inadequate;

- Patients with epithelial herpes simplex (dendritic keratitis), vaccinia, varicella,

or other viral disease of the cornea or conjunctiva, tuberculosis of the eye, fungal diseases of ocular structures;

- Patients who use a topical ophthalmic prostaglandin, such as ,Travatan®

(travoprost),Xalatan®(latanoprost),Lumigan®(bimatoprost)and Rescula®(unoprostone) should discontinue their use starting four days before surgery until their departure from study.

Locations and Contacts

Rubens Belfort, investigator, Phone: 5511 5572-6443, Email: prof.belfort@clinicabelfort.com.br

Universidade Federal de São Paulo - Hospital São Paulo - UNIFESP, São Paulo, SP/Brazil 4562-020, Brazil; Not yet recruiting
Rubens Belfort, investigator, Phone: 55115572-6443, Email: prof.belfort@clinicabelfort.com.br
Luci Silva, coordinator, Phone: 55115572-6443, Email: luci@oftalmo.epm.br
Rubens Belfort, MD, Principal Investigator
Additional Information

Starting date: June 2012
Last updated: May 21, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017